Company profile: FogPharma
1.1 - Company Overview
Company description
- Provider of precision medicines based on Helicons, a new class combining antibody-like targeting with broad tissue distribution and intracellular target engagement of small molecules; pipeline includes FOG-001, a first-in-class TCF-blocking β-catenin inhibitor (Phase 1/2), β-catenin and ERG degraders, an ERG/DNA binding inhibitor (discovery), and Helicon-enabled alpha radioligand therapies (hit identification).
Products and services
- FOG-001: A first-in-class, clinical-stage TCF-blocking β‑catenin inhibitor in Phase 1/2 trial, engineered to block β‑catenin‑driven TCF activity
- Helicons: A precision-medicine class combining antibody-like targeting strength and specificity with small-molecule broad tissue distribution and intracellular target engagement, extending reach across the vast majority of therapeutic targets
- β‑catenin Degrader: A discovery-stage therapeutic targeting β‑catenin, designed to degrade β‑catenin protein and reduce β‑catenin levels via degradation
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to FogPharma
F-star
HQ: United Kingdom
Website
- Description: Provider of novel bispecific antibody therapeutics focused on immuno-oncology and oncology, developing bispecific antibody products to improve the standard of care, with the ability to create and develop Fcab™ antibody fragments.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full F-star company profile →
Origo Biopharma
HQ: Spain
Website
- Description: Provider of research and development of immunotherapeutic products targeting health disorders related to TGF-beta signaling dysfunction, including cancer and fibrosis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Origo Biopharma company profile →
PanTher Therapeutics
HQ: United States
Website
- Description: Provider of localized cancer therapies leveraging the Sagittari platform to optimize drug dose and duration for high-dose, tumor-targeted treatment with minimal systemic exposure. Offers PTM-101, a clinical-stage candidate delivering high concentrations of paclitaxel to pancreatic tumors via minimally invasive laparoscopy, and exploratory programs for pancreatic, colon, and lung cancers.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full PanTher Therapeutics company profile →
PMV Pharma
HQ: United States
Website
- Description: Provider of p53-targeted small molecule therapeutics for cancer, including the investigational candidate rezatapopt (PC14586) designed to reactivate the p53 Y220C mutation for advanced solid tumors. Offers drug discovery focused on restoring mutant p53 tumor suppressor function and conducts clinical trials to assess safety and efficacy in patients with specific p53 mutations.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full PMV Pharma company profile →
Sonalasense
HQ: United States
Website
- Description: Provider of noninvasive sonodynamic therapy (SDT) that combines a proprietary intravenous ALA formulation (SONALA-001) with MR-guided focused ultrasound to induce necrosis and apoptosis in gliomas, including glioblastoma multiforme (GBM); conducts clinical trials in solid tumors and advances a pipeline to expand indications across multiple tumor types.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sonalasense company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for FogPharma
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to FogPharma
2.2 - Growth funds investing in similar companies to FogPharma
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for FogPharma
4.2 - Public trading comparable groups for FogPharma
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →